Company & Sponsor Intelligence
Cephalon
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting0
Completed5
Countries1
Therapeutic footprint
adhddepressionpain_neuropathyparkinsonsschizophrenia
Indexed studies
NCT00040404Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
parkinsons · United StatesPHASE2, PHASE3
parkinsons · United StatesPHASE2, PHASE3
NCT01072630Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT00315276Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
adhd · United StatesPHASE2
adhd · United StatesPHASE2
NCT00813488Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain
pain_neuropathy · United StatesPHASE3
pain_neuropathy · United StatesPHASE3
NCT00772005Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
schizophrenia · United StatesPHASE2
schizophrenia · United StatesPHASE2
NCT00343733Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
pain_neuropathy · United StatesPHASE3
pain_neuropathy · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →